Rösch AG Medizintechnik
Rösch AG Medizintechnik english

Rösch AG and STADA Arzneimittel AG: Co-operation on the needle-free application Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rösch AG and STADA Arzneimittel AG: Co-operation on the needle-free application of low-molecular heparin STADA Arzneimittel AG intends to distribute under licence the INJEX OneWay system developed by Rösch AG for the needle free application of low-molecular heparin. A known active ingredient in the prevention of thrombosis, low- molecular heparin can, thanks to INJEX OneWay, now be applied in a new, less painful and thus more user-friendly way. Rösch considers that the innovative therapeutic concept enjoys outstanding marketing potential both in Europe and across the world, since the overall market for thrombosis prophylactics is estimated to be worth EUR 750 million in Europe and approx. EUR 2 billion worldwide. The signed letter of intent provides for the exclusive marketing of INJEX OneWay by STADA in Europe. The companies anticipate entering into a licensing agreement when negotiations are completed in the near future, with a market launch expected in 2004. Rösch is hoping that the licensing agreement will give it better distribution access to the market and thus stimulate its own new developments. Rösch’s Chief Executive, Mr Weidler, is optimistic: ‘Our needle- free technology will continue to gain acceptance.’ In setting up this collaboration, STADA is consistently pursuing its own strategic objective, which is to concentrate on patent-free active ingredients in attractive market segments with slim internal corporate structures. ‘We do not have to develop everything ourselves. By buying a licence, we can test at reduced risk to ourselves how the market will react to a new therapeutic concept for a known drug’, comments STADA’s Chief Executive Hartmut Retzlaff on the proposed licensing agreement. For more information, please contact: Rösch AG Medizintechnik / Investor Relations / 12349 Berlin / Tel.: +49(0) 30 66 79 15-0 / Fax: +49(0) 30 66 79 15-66 / E-mail: vorstand@roesch-ag.de / Internet: www.roesch-ag.de or STADA Arzneimittel AG / Unternehmenskommunikation / 61118 Bad Vilbel Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communication@stada.de / Internet: www.stada.de end of ad-hoc-announcement (c)DGAP 02.07.2002 ——————————————————————————– WKN: 529 140; ISIN: DE0005291405; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 020841 Jul 02